Clinical Trial Update: Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of CHF 5993 HFA-152a inhaled formulation in asthma patients uncontrolled on medium-dose inhaled cortic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF 5993 HFA-152a inhaled formulation (pMDI) (CHF 5993)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: NOT_YET_RECRUITING